Association of diethylhexyl phthalate with obesity-related markers and body mass change from birth to 3 months of age

Jin Hee Kim,1 Hyunkyung Park,1 Jangwoo Lee,1 Geumjoon Cho,2 Sooran Choi,3,4 Gyuyeon Choi,5 Su Young Kim,6 So-Hee Eun,2 Eunsook Suh,5 Sung Koo Kim,4 Hai-Joong Kim,2 Gun-Ha Kim,2 Jeong Jae Lee,5 Young Don Kim,6 Soyong Eom,7 Seunghyo Kim,6 Hyo-Bang Moon,8 Jeongim Park,9 Kyungho Choi,1 Sungjoo Kim,4 Sungkkyoon Kim1

ABSTRACT

Background Several studies have suggested potential links of phthalates to obesity in children and adults. Limited evidence, however, has been available for the relations between diethylhexyl phthalate (DEHP) and obesity-related markers or body mass change in early life.

Methods 128 healthy pregnant women were recruited and, after delivery, their newborns’ first urine and umbilical cord blood samples were collected. We measured urinary levels of two DEHP metabolites, mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) and mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP). We also measured the levels of leptin, total cholesterol and triglyceride (TG) in cord serum, and used them along with weight, length, head circumference and ponderal index (PI, 100 g/cm3) at birth, as obesity-related markers, and estimated the relations between DEHP metabolites and obesity-related markers using generalised linear models. For the evaluation of body mass increase by early life DEHP exposure, body mass index (BMI) z-score change during 3 months after birth by DEHP metabolites in the first urine samples of the newborns were evaluated using logistic regression.

Results DEHP exposure was associated with decrease of PI and increase of TG (PI, β=−0.11, p=0.070 and TG, β=0.14, p=0.027), especially for boys (PI, β=−0.13, p=0.021; and TG, β=0.19, p=0.025). Moreover, DEHP exposure was positively associated with body mass increase during 3 months after birth (change of BMI z-scores, OR=4.35, p=0.025).

Conclusions Our findings suggest that DEHP exposure may affect body mass change in early life through changes of obesity-related markers.

INTRODUCTION

Phthalates have been known to contribute to a high prevalence of various symptoms including obesity and diabetes mellitus. Among phthalates, diethylhexyl phthalate (DEHP) has been used as a dominant plasticiser of polyvinyl chloride-containing products. Since DEHP is easily separated from plastic, people are frequently exposed to it. Owing to its potential adverse effects on human health and humans’ ubiquitous exposure to it, the European Union has put DEHP under regulation8 and California, in 2009, banned its use in children’s toys.9 Although several reports have suggested a significant association between phthalate exposures and obesity in children and adults,1 4 little is known about how DEHP causes obesity in humans and whether DEHP exposure affects obesity development in early life as well as in childhood and adulthood.1 3 6

Many studies reported DEHP metabolite levels in each medium of pregnant women, cord blood and breast milk, and suggested that exposure to DEHP in early life may be no less important than exposure later in life.7 10 Recently, early-life exposure to endocrine disruptors including DEHP was suggested to cause permanent metabolic alterations,11 potentially increasing the chance of obesity later in life, and leading to various diseases such as hypertension and diabetes mellitus.6

In the present study, we investigated whether exposure to DEHP is associated with obesity-related markers and, by extension, whether its perinatal exposure might affect body mass change in early life. Therefore, we measured levels of DEHP metabolites in newborns’ urine as well as maternal blood, maternal urine, placenta and cord blood samples, and evaluated the effects of DEHP exposure on obesity-related markers and body mass change for the first 3 months after birth.

METHODS

Study population and sampling

The Children’s Health and Environmental Chemicals in Korea (CHECK) Study was launched in January 2011, to explore relationships between environmental exposures and health outcomes in children. Totally, 335 pregnant women with a healthy mature singleton were recruited based on volunteering, from the general population at five university hospitals in Seoul, Pyungchon, Ansan and Jeju, Republic of Korea. We selected 128 women among them, who gave birth between February and December, 2012, and used the standard operating procedure described earlier for sample collection/treatment. Detailed information of the participants was obtained through face-to-face interviews with a structured questionnaire, for personal characteristics and pregnancy-related information, including age, weight, height, income, gestational period, caesarean section and past delivery experience. Body weight, length and
head circumference of the newborns were measured directly after birth, and weight and length 3 months after birth were ascertained later through a telephone interview. Blood and urine samples of the pregnant women were collected as soon as they came to hospital on the day before delivery, and placenta along with umbilical cord blood were collected during delivery; the newborns’ first urine samples were collected by nurses, using polyethylene urine-collection bags (Urine Collector, ROOTICS Corp, Korea) within 2 days postpartum. Maternal and cord blood was directly collected in a serum separation tube (SST), using a needle connected to a vacutainer made from polyethylene (BD Vacutainer SST II Advance, ref # 367953, Becton-Dickinson, UK), and centrifuged at 3000 rpm for 10 min. The sera were then transferred to a 1 mL polyethylene cryotube with screw cap. All samples were stored at −80°C until analysis. Each study participant provided written informed consent. The study protocol was conducted in accordance with guidelines laid down in the Declaration of Helsinki, and all procedures were approved by the Institutional Review Board at School of Public Health, Seoul National University, Korea (IRB number 8-2012-04-20).

**Measurement of DEHP metabolites**

Based on the recommendation for selecting exposure biomarkers of DEHP, we selected mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) and mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP), metabolites of DEHP as DEHP exposure markers. Levels of MEHHP and MEOHP were measured in blood, urine and placenta samples using procedures presented in online supplementary methods.13-16 Information regarding quality assurance and control are described in online supplementary methods and tables S1-S4.

**Measurement of leptin, total cholesterol and triglyceride (TG)**

The levels of leptin, total cholesterol and TG in cord serum were measured as obesity-related markers by procedures presented in online supplementary methods.17

**Statistical analyses**

Basic characteristics in newborn boys and girls were compared using a t test or χ² test. DEHP metabolite concentrations under limit of detection (LOD) were assigned as a default value of LOD divided by √2. Distribution of DEHP metabolites in blood, placenta and urine samples, and ratios of DEHP metabolites in newborns’ and mothers’ samples, were analysed. The associations among DEHP metabolite levels in maternal blood, maternal urine, cord blood, placenta and newborns’ urine samples, were estimated using Spearman correlation. The effect of DEHP metabolites in newborns’ urine on obesity-related markers and body mass index (BMI) change was evaluated using a generalised linear model, where the common log of each level of obesity-related markers (birth weight, birth length, head circumference at birth, ponderal index (PI, 100 g/cm³), leptin, total cholesterol and TG) was regressed on the corresponding common log of the DEHP metabolites in the newborn’s first urine by the newborn’s sex after adjustment for maternal age (years), maternal BMI (kg/m²), gestational period (days), caesarean section (0=no/1=yes), delivery experience (0=no/1=yes) and urinary creatinine level (mg/dL). To evaluate the change of body mass for the first 3 months after birth by DEHP exposure, we calculated change of BMI z-scores, \( \Delta z = \frac{BMI_0 - BMI_{100}}{SD_0} - \frac{BMI_0 - BMI_{110}}{SD_1} \), where BMI₀, BMI₁₀₀ and BMI₁₁₀ were the mean BMIs at birth and the third month, BMI₀, BMI₁₀₀ and BMI₁₁₀ were individual BMIs at birth and the third month, and SD₀ and SD₁ were standard deviations of BMIs at birth and the third month, respectively, and then evaluated the effects of the common log of the urinary biomarkers of DEHP on the change of BMI z-score using logistic regression after adjustment for covariates used in the generalised linear model plus newborn’s sex (0=boy/1=girl), common log of PI (100 g/cm³) and common log of TG (mg/dL). The evaluation criterion for relative body mass increase was BMI z-score change (Δz) more than the 50th centile.

All analyses used two-sided tests, with a p value lower than 0.05 as statistically significant. SAS V9.4 Enterprise (SAS Institute Inc, Cary, North Carolina, USA) and R V3.1.2 (The Comprehensive R Archive Network: http://cran.r-project.org) were used for statistical analyses.

**RESULTS**

A total of 128 healthy pregnant women and their newborns (65 boys and 63 girls) were included in this study. Leptin levels in cord blood were significantly different between boys and girls (p=0.002), while others were not different (table 1). DEHP metabolite concentrations were measured in maternal blood (n=105), maternal urine (n=116), cord blood (n=101), placenta (n=115) and newborns’ urine (n=73) samples (table 2). While MEOHP was detected in all urine samples but not in those of most blood and placenta, MEHHP was detected in all sample media. Geometric mean (GM) was 0.31 ng/mL for MEHHP in maternal blood, 18.23 ng/mL for MEHHP and 15.88 ng/mL for MEOHP in maternal urine, 0.33 ng/mL for MEHHP in cord blood, 0.10 ng/g for MEOHP in placenta and 5.83 ng/mL for MEHHP and 3.02 ng/mL for MEOHP in newborns’ urine samples (table 2). GM for MEOHP in blood samples was not

---

**Table 1** Characteristics of the participants

| Characteristics                  | Newborn’s sex (median (IQR) or n (%)) | p Value |
|----------------------------------|-------------------------------------|---------|
| Maternal age (years)             | Boys (n=65) | Girls (n=63) | 0.083 |
| Maternal body mass index (kg/m²) | 33 (30–36) | 34 (32–38) | 0.816 |
| Gestational period (days)        | 275 (268–280) | 277 (270–282) | 0.277 |
| Caesarean section                | No | 17 (26.2) | 16 (25.4) | 0.922 |
| Delivery experience              | Yes | 19 (29.2) | 22 (34.9) | 0.490 |
| Income (US$/month)               | 17 (28.3) | 14 (26.9) | 0.891 |
| Birth weight (kg)                | 27 (45.0) | 22 (42.3) | 0.272 |
| Birth length (cm)                | 50 (49–52) | 50 (48–52) | 0.584 |
| Head circumference at birth (cm) | 34 (33–35) | 34 (33–35) | 0.133 |

---

Kim JH, et al. J Epidemiol Community Health 2016;70:466–472. doi:10.1136/jech-2015-206315 467
birth, urinary DEHP metabolites were positively associated with $p=0.020$; and

Interestingly, MEOHP levels in maternal urine and newborns showed significant positive correlation between maternal urine and cord blood samples ($p=0.001$). MEOHP levels also showed similar positive correlation between maternal blood and cord blood, and between maternal urine and newborns’ urine (both, $p<0.05$), but showed negative correlation between maternal urine and cord blood samples ($p=0.001$). Interestingly, MEOHP levels in maternal urine and newborns’ urine samples were found to be positively associated with MEHHP levels in all media (all, $p<0.05$).

The effects of each DEHP metabolite and sum of MEHHP and MEOHP ($\sum$DEHP) on obesity-related markers are summarised in table 5. Urinary MEHHP and MEOHP levels were negatively associated with PI ($\beta=0.10, p=0.066$; and MEOHP, $\beta=-0.11, p=0.083$), and positively associated with TG levels (MEHHP, $\beta=0.15, p=0.024$; and MEOHP, $\beta=0.13, p=0.042$). In summary, urinary levels of $\sum$DEHP were also negatively associated with PI and positively associated with TG levels (PI, $\beta=-0.11, p=0.070$; and TG, $\beta=0.14, p=0.027$; decrease of 12.7 g/cm$^3$ (48%) of PI and increase of 1.39 mg/dL (4.6%) of TG by increase of 10 ng/mL of $\sum$DEHP). The negative association of DEHP metabolites with PI was more apparent in boys (MEHHP, $\beta=-0.13, p=0.022$; MEOHP, $\beta=-0.13, p=0.020$; and $\sum$DEHP, $\beta=-0.13, p=0.021$).

Regarding body mass change during the first 3 months after birth, urinary DEHP metabolites were positively associated with changes of BMI z-scores from birth to 3 months after birth ($\beta=0.88, p<0.001$; see online supplementary table S6), and both MEHHP and MEOHP showed a significantly increased odds ratio (OR) for body mass increase over the 50th centile (MEHHP OR=4.43, $p=0.023$; MEOHP OR=3.91, $p=0.032$; and $\sum$DEHP OR=4.35, $p=0.025$; table 5).

DISCUSSION

One of the features of the present study is that we used all available biological tissues from matched mother-newborn pairs. We explored the distribution of exposure biomarkers of DEHP among the tissues, and tried to investigate relationship between perinatal DEHP exposure and potential health outcomes linked to obesity in early life.

In this study, we evaluated MEHHP and MEOHP levels as DEHP exposure markers. Urinary DEHP metabolite concentrations in the present study were higher than those in a study of German mothers and their healthy newborns (median, 5.6 ng/mL for MEHHP and 4.8 ng/mL for MEOHP in mothers, and 1.7 ng/mL for MEHHP and 1.3 ng/mL for MEOHP in newborns) but similar to those in full-term infants from birth to 14 months of age in a study from Finland (median, 5.01 ng/mL for MEHHP and 3.90 ng/mL for MEOHP), which found more abundance of MEHHP relative to MEOHP in all media, which was consistent with other studies on newborns from days 2–5, children at 2 or 5 years old and pregnant women, and partially supported by a human pharmacokinetic study with oral administration of deuterium-labelled DEHP.

In the estimation of relations among media for DEHP metabolite levels, MEHHP and MEOHP levels in our study showed generally good correlations among media, particularly for MEHHP. Although MEOHP levels showed positive correlations between maternal blood and cord blood, and between maternal urine and newborns’ urine, negative correlation was also found between maternal urine and cord blood for MEOHP. It may be due to small samples detected for MEOHP in cord blood. Therefore, positive correlations of MEOHP levels between maternal and cord blood and negative correlation between maternal urine and cord blood should be carefully interpreted. However, positive correlations of MEHHP levels among media,

| Metabolite | n | n>LOD (%) | GM (GSD) | 10th | 25th | 50th | 75th | 90th |
|-----------|---|-----------|----------|------|------|------|------|------|
| Maternal blood | | | | | | | | |
| MEHHP (ng/mL) | 105 | 105 (100) | 0.31 (0.05) | 0.27 | 0.29 | 0.31 | 0.33 | 0.39 |
| MEOHP (ng/mL) | 105 | 1 (1.0) | – | <LOD | <LOD | <LOD | <LOD | <LOD |
| Maternal urine | | | | | | | | |
| MEHHP (ng/mL) | 116 | 116 (100) | 18.23 (28.82) | 5.03 | 10.39 | 17.74 | 17.74 | 60.42 |
| MEOHP (ng/mL) | 116 | 116 (100) | 15.88 (27.58) | 4.93 | 9.33 | 14.70 | 29.55 | 52.41 |
| Cord blood | | | | | | | | |
| MEHHP (ng/mL) | 101 | 101 (100) | 0.33 (0.05) | 0.28 | 0.30 | 0.32 | 0.35 | 0.39 |
| MEOHP (ng/mL) | 101 | 2 (2.0) | – | <LOD | <LOD | <LOD | <LOD | <LOD |
| Placenta | | | | | | | | |
| MEHHP (ng/g) | 115 | 115 (100) | 0.10 (0.02) | 0.08 | 0.08 | 0.09 | 0.11 | 0.14 |
| MEOHP (ng/g) | 115 | 1 (0.9) | – | <LOD | <LOD | <LOD | <LOD | <LOD |
| Newborns’ urine | | | | | | | | |
| MEHHP (ng/mL) | 73 | 73 (100) | 5.83 (10.79) | 1.33 | 3.21 | 5.79 | 11.87 | 19.08 |
| MEOHP (ng/mL) | 73 | 73 (100) | 3.02 (6.15) | 0.64 | 1.51 | 3.27 | 6.50 | 10.00 |

DEHP, diethylhexyl phthalate; GM, geometric mean; GSD, geometric SD; MEHHP, mono-(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, mono-(2-ethyl-5-oxohexyl) phthalate.
Table 3  Correlations of DEHP metabolites among multiple biological samples

| Covariate | Spearman correlation coefficient (p Value) |
|-----------|-------------------------------------------|
| 1. MEHHP in maternal blood (ng/mL) | 1.000 (1) | 0.443 (<0.001) | 0.330 (0.001) | 0.346 (0.010) | -0.069 (0.484) | 0.418 (<0.001) | -0.221 (0.027) | 0.069 (0.484) | 0.418 (<0.001) |
| 2. MEHHP in maternal urine (μg/g creatinine) | 1.000 (1) | 0.310 (0.002) | 0.404 (<0.001) | 0.357 (0.004) | -0.155 (0.118) | 0.941 (<0.001) | -0.311 (0.001) | -0.054 (0.577) | 0.340 (0.007) |
| 3. MEHHP in cord blood (ng/mL) | 1.000 (1) | 0.280 (0.052) | 0.430 (0.001) | -0.058 (0.566) | 0.397 (<0.001) | -0.339 (0.001) | 0.163 (0.108) | -0.150 (0.670) | 0.340 (0.007) |
| 4. MEHHP in placenta (ng/mL) | 1.000 (1) | 0.431 (0.001) | -0.061 (0.540) | 0.418 (<0.001) | -0.177 (0.080) | 0.150 (0.119) | 0.425 (0.001) | 0.425 (0.001) | 0.425 (0.001) |
| 5. MEHHP in newborn infants’ urine (μg/g creatinine) | 1.000 (1) | 0.127 (0.354) | 0.382 (0.002) | -0.105 (0.454) | 0.082 (0.525) | 0.960 (<0.001) | 0.425 (0.001) | 0.425 (0.001) | 0.425 (0.001) |
| 6. MEOHP in maternal blood (ng/mL) | 1.000 (1) | -0.155 (0.118) | 0.424 (<0.001) | 0.006 (0.954) | 0.079 (0.569) | 0.079 (0.569) | 0.079 (0.569) | 0.079 (0.569) | 0.079 (0.569) |
| 7. MEOHP in maternal urine (μg/g creatinine) | 1.000 (1) | 0.319 (0.001) | -0.057 (0.556) | 0.380 (0.002) | -0.133 (0.342) | 0.380 (0.002) | -0.133 (0.342) | 0.380 (0.002) | 0.380 (0.002) |
| 8. MEOHP in cord blood (ng/mL) | 1.000 (1) | 0.339 (0.001) | -0.163 (0.108) | 0.442 (0.001) | -0.177 (0.080) | 0.150 (0.119) | 0.425 (0.001) | 0.425 (0.001) | 0.425 (0.001) |
| 9. MEOHP in placenta (ng/mL) | 1.000 (1) | 0.339 (0.001) | -0.163 (0.108) | 0.442 (0.001) | -0.177 (0.080) | 0.150 (0.119) | 0.425 (0.001) | 0.425 (0.001) | 0.425 (0.001) |
| 10. MEOHP in newborn infants’ urine (μg/g creatinine) | 1.000 (1) | 0.339 (0.001) | -0.163 (0.108) | 0.442 (0.001) | -0.177 (0.080) | 0.150 (0.119) | 0.425 (0.001) | 0.425 (0.001) | 0.425 (0.001) |

DEHP, diethylhexyl phthalate; MEHPP, mono-(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, mono-(2-ethyl-5-oxohexyl) phthalate.

and positive correlation of MEOHP levels between maternal serum and urine, support urinary metabolites in newborns and positive correlation of MEHHP levels in cord serum and maternal serum. Previous studies have shown that DEHP and DEHP metabolites can cross the placenta and be excreted in breast milk and urine, indicating the occurrence of perinatal exposure to DEHP. Moreover, the ratio of MEHHP (or DEHP metabolite) was increased in cord serum and maternal serum. This may be due to the difference of postnatal dietary intake in our models, because type and amount of breast milk intake may only be influenced by DEHP exposure in early life. The young age of DEHP metabolites in cord serum may allow us to assess the level of PI in cord serum and in maternal serum can allow us to determine perinatal exposure to DEHP. Moreover, the ratio of MEHHP (or DEHP metabolite) was increased in cord serum and maternal serum. This may be due to the difference of postnatal dietary intake in our models, because type and amount of breast milk intake may only be influenced by DEHP exposure in early life. The young age of DEHP metabolites in cord serum may allow us to assess the level of PI in cord serum.

We did not adjust for newborns' diet in our model although it could be an important factor affecting the body mass of infants. We found bigger OR for BMI z-score increase by DEHP exposure although it was not significant due to small sample size (data not shown here). Moreover, breast milk as another DEHP source may not be a confounder because type and amount of breast milk intake may only be influenced by DEHP exposure in early life. The young age of DEHP metabolites in cord serum may allow us to assess the level of PI in cord serum.

Moreover, exposure to DEHP in our study showed a marginally significant association for BMI z-score increase (OR: 2.25, 95% CI: 1.11 to 4.59, p = 0.027) after controlling for newborns' diet in our model although it could be an important factor affecting the body mass of infants. We found bigger OR for BMI z-score increase by DEHP exposure although it was not significant due to small sample size (data not shown here). Moreover, breast milk as another DEHP source may not be a confounder because type and amount of breast milk intake may only be influenced by DEHP exposure in early life. The young age of DEHP metabolites in cord serum may allow us to assess the level of PI in cord serum.

Moreover, exposure to DEHP in our study showed a marginally significant association for BMI z-score increase (OR: 2.25, 95% CI: 1.11 to 4.59, p = 0.027) after controlling for newborns' diet in our model although it could be an important factor affecting the body mass of infants. We found bigger OR for BMI z-score increase by DEHP exposure although it was not significant due to small sample size (data not shown here). Moreover, breast milk as another DEHP source may not be a confounder because type and amount of breast milk intake may only be influenced by DEHP exposure in early life. The young age of DEHP metabolites in cord serum may allow us to assess the level of PI in cord serum.
exposure source was fed after first urine collection in the present study and thus it may not affect perinatal DEHP exposure in newborns. Furthermore, we used the same procedure of caring for newborns before urine collection to rule out other DEHP exposure factors. In addition, we checked the difference between DEHP metabolites by sources of DEHP exposure plausible during delivery and after birth, for example, between regular and caesarean births, and among five hospitals, because DEHP may be used for some medical products. However, we did not find any difference between regular and caesarean births, and among hospitals (data not shown here).

The strength of the present study was the cohort design using various media. This study design allows for the evaluation of the effects of DEHP exposures on obesity-related markers and body mass change in early life. While only healthy newborns, not those who were obese or without low birth weight, were included in this study, we found significant associations of urinary DEHP metabolite levels in newborns with obesity-related markers and body mass change in early life. Since DEHP metabolites in urine are known to be valid exposure biomarkers compared with those in other media, we used urinary levels of MEHHP and MEOHP as exposure biomarkers in newborns to evaluate DEHP exposure in early life. However, we also found good correlation between the levels of MEHHP and MEOHP in newborns’ urine and those in various media, indicating a possibility representing in utero DEHP exposure in newborns.

On the other hand, our study had limitations as well. We did not consider temporality of exposure to DEHP although DEHP metabolites have been considered as representative of acute exposures due to their short half-life. However, DEHP measures were reproducible from one day to the next in spite of a great deal of variability in DEHP exposure because lifestyle habits may not change quickly. Since we got information such as gestational age, weight and length of infants at birth and at 3 months basically by interviewing, not by reviewing medical charts, information bias could not be ruled out. However, such an error is likely to be non-differential, which generally shifts the associations toward the null. In addition, we did not consider other endocrine disrupting chemicals (EDCs) except DEHP. Because EDCs known to be obesityins including persistent organic pollutants, bisphenol A, and other phthalates except for DEHP may be co-exposed to participants of the present study mixed effects of EDCs should be further studied in the future.

### Table 4 The effects of DEHP metabolites in newborns’ urine on obesity-related markers

| Exposure | Outcome | Total | Boys | Girls |
|----------|---------|-------|-------|-------|
|          | β       | 95% CI | p Value | β       | 95% CI | p Value | β       | 95% CI | p Value |
| MEHHP    | Birth weight | -0.003 | 0.032 | 0.872 | -0.003 | 0.045 | 0.889 | -0.020 | 0.034 | 0.483 |
|          | Birth length | 0.031 | 0.072 | 0.104 | 0.048 | 0.080 | 0.008 | -0.044 | 0.036 | 0.378 |
|          | Head circumference at birth | 0.004 | 0.017 | 0.586 | 0.0004 | 0.020 | 0.970 | 0.013 | 0.030 | 0.166 |
|          | Ponderal index at birth | -0.105 | 0.004 | 0.066 | -0.129 | 0.026 | 0.022 | 0.045 | 0.253 | 0.774 |
|          | Leptin in cord blood | -0.069 | 0.211 | 0.642 | 0.083 | 0.365 | 0.567 | -0.440 | -1.271 | 0.334 |
|          | Total cholesterol in cord blood | -0.281 | 0.062 | 0.620 | -0.010 | 0.114 | 0.954 | -0.044 | -0.168 | 0.502 |
|          | Triglyceride in cord blood | 0.146 | 0.024 | 0.272 | 0.024 | 0.340 | 0.022 | 0.050 | -0.191 | 0.695 |
| MEOHP    | Birth weight | 0.002 | 0.037 | 0.897 | 0.003 | 0.046 | 0.501 | -0.021 | 0.030 | 0.471 |
|          | Birth length | 0.030 | 0.067 | 0.115 | 0.052 | 0.085 | 0.004 | -0.042 | 0.038 | 0.388 |
|          | Head circumference at birth | 0.006 | 0.019 | 0.381 | 0.003 | 0.024 | 0.768 | 0.013 | 0.030 | 0.158 |
|          | Ponderal index at birth | -0.099 | 0.010 | 0.083 | -0.133 | 0.028 | 0.020 | 0.037 | -0.255 | 0.810 |
|          | Leptin in cord blood | -0.309 | -0.254 | 0.795 | 0.080 | 0.370 | 0.591 | -0.323 | -1.175 | 0.481 |
|          | Total cholesterol in cord blood | -0.014 | -0.070 | 0.744 | -0.008 | -0.098 | 0.883 | -0.032 | -0.157 | 0.932 |
|          | Triglyceride in cord blood | 0.132 | 0.025 | 0.042 | 0.181 | 0.338 | 0.032 | 0.025 | -0.217 | 0.845 |
| DEHP     | Birth weight | -0.001 | 0.035 | 0.960 | -0.001 | 0.048 | 0.976 | -0.021 | 0.075 | 0.340 |
|          | Birth length | 0.031 | 0.069 | 0.104 | 0.050 | 0.082 | 0.006 | -0.044 | -0.136 | 0.374 |
|          | Head circumference at birth | 0.005 | 0.018 | 0.502 | 0.001 | 0.022 | 0.935 | 0.013 | 0.031 | 0.157 |
|          | Ponderal index at birth | -0.105 | 0.006 | 0.070 | -0.132 | -0.027 | 0.021 | 0.044 | -0.256 | 0.779 |
|          | Leptin in cord blood | -0.059 | -0.353 | 0.697 | 0.085 | 0.371 | 0.564 | -0.410 | -1.260 | 0.375 |
|          | Total cholesterol in cord blood | -0.019 | -0.065 | 0.657 | -0.009 | -0.096 | 0.868 | -0.041 | -0.167 | 0.539 |
|          | Triglyceride in cord blood | 0.144 | 0.027 | 0.207 | 0.188 | 0.034 | 0.825 | 0.042 | -0.202 | 0.742 |

The effect of DEHP metabolites in newborns’ urine on obesity-related markers was evaluated using a generalised linear model, where the common log of each level of obesity-related markers (birth weight [kg], birth length [cm], head circumference at birth [cm], ponderal index [PI, 100 g/cm²], leptin [ng/mL], total cholesterol [mg/dL] and TG [mg/dL]), was regressed on the corresponding common log of the DEHP metabolites (ng/mL) in the newborn’s first urine after adjustment for maternal age (years), maternal BMI (kg/m²), gestational period (days), caesarean section (0—not—1=—yes), delivery experience (0—not—1=—yes) and urinary creatinine level (mg/dL). DEHP, sum of MEHHP and MEOHP. MEOHP, mono-(2-ethyl-5-oxohexyl) phthalate; MEHHP, mono-(2-ethyl-5-hydroxyhexyl) phthalate; MEHHP, mono-(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, mono-(2-ethyl-5-oxohexyl) phthalate.

### Table 5 Change of BMI z-scores from birth to 3 months after birth by change of DEHP metabolites

| Exposure | OR   | 95% CI         | p Value |
|----------|------|----------------|---------|
| MEHHP    | 4.43 | 1.22 – 16.04    | 0.023   |
| MEOHP    | 3.91 | 1.12 – 13.65    | 0.032   |
| DEHP     | 4.35 | 1.20 – 15.72    | 0.025   |

The effect of common log of DEHP metabolite in newborns’ urine on the change of BMI z-score was evaluated using logistic regression after adjustment for covariates used in the generalised linear model plus newborns’ sex (0=—girl—1=—boy), common log of ponderal index (PI, 100 g/cm²) and common log of triglyceride (TG, mg/dL). Evaluation criterion for relative body mass increase was BMI z-score change over the 50th centile. DEHP, sum of MEHHP and MEOHP. BMI, body mass index; DEHP, diethylhexyl phthalate; MEHHP, mono-(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, mono-(2-ethyl-5-oxohexyl) phthalate.
In conclusion, this study suggests that DEHP exposure may decrease PI and increase TG levels in newborn infants, finally resulting in body mass increase in early life. However, further epidemiological studies with large sample sizes are needed to confirm our findings.

What is already known on this subject

- Phthalate has been suggested to increase obesity in children and adults.
- Obesity in early life is associated with obesity later in life leading to development of obesity-related diseases.
- Limited evidence has been available for the relations between diethylhexyl phthalate (DEHP), a dominant plasticiser, and obesity-related markers or body mass change in early life.

What this study adds

- Exposure to DEHP is associated with decrease of ponderal index and increase of triglyceride at birth.
- Body mass increase is accelerated in newborn infants exposed to DEHP.
- Given the association of DEHP with obesity-related markers and body mass change in early life, efforts in reducing DEHP exposure in early life may be important for potentially decreasing the chance of obesity later in life leading to various diseases.

Author affiliations
1Department of Environmental Health, Graduate School of Public Health, Seoul National University, Seoul, Republic of Korea
2College of Medicine, Korea University, Seoul, Republic of Korea
3College of Medicine, Inha University, Incheon, Republic of Korea
4College of Medicine, Hallym University, Seoul, Republic of Korea
5College of Medicine, Soonchunhyang University, Seoul, Republic of Korea
6Jeju National University School of Medicine, Jeju, Republic of Korea
7College of Medicine, Yonsei University, Seoul, Republic of Korea
8Department of Marine Sciences and Convergent Technology, Hanyang University, Ansan, Republic of Korea
9College of Natural Sciences, Soonchunhyang University, Asan, Republic of Korea

Acknowledgements The authors thank Su-Jin Lee for assisting with data collection.

Contributors JHK designed the study, analysed data and wrote the manuscript. HP, JL, GeC, ScC, GeC, SYK, S-HK, ES, SKK, H-JK, G-HK, JIL, YDK, SE and SEK were responsible for interviewing participants, acquiring the data and cleaning the collected data. H-BM, JP, KC, SungK and SungKK were responsible for drafting and reviewing the manuscript.

Funding This study was supported by the Korea Food and Drug Administration (12162MFDS731).

Competing interests None declared.

Patient consent Obtained.

Ethics approval The present study was approved by the institutional review board at School of Public Health, Seoul National University, Korea (IRB number 8–2012-04-20).

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES
1 Stahlhut RW, van Wijngaarden E, Dye TD, et al. Concentrations of urinary phthalate metabolites are associated with increased waist circumference and insulin resistance in adult U.S. Males. Environ Health Perspect 2007;115:876–82.
2 European Chemicals Agency. 2012. http://echa.europa.eu/en/view-article/journal_ content/title/proposal-to-restrict-four-classified-phthalates-under-reach-not-justified (accessed 13 Jun 2013).
3 Hileman B. California bans phthalates in toys for children. Chemical and engineering news. 2007. http://pubs.acs.org/doi/abs/10.1021/ed085m3.854n08.001 (accessed 13 Jun 2013).
4 Trasande L, Attina TM, Sathyanarayana S, et al. Race/ethnicity-specific associations of urinary phthalates with childhood body mass in a nationally representative sample. Environ Health Perspect 2013;121:501–6.
5 Hellerstedt WL, McGovern PM, Fontaine P, et al. Prenatal environmental exposures and child health: Minnesota’s role in the National Children’s Study. Minn Med 2008;91:40–3.
6 Schmidt JS, Schaudelhi K, Flandraus NL, et al. Effects of di(2-ethylhexyl) phthalate (DEHP) on female fertility and adipogenesis in C3H/He mice. Environ Health Perspect 2012;120:1123–9.
7 Frederiksen H, Skakkebaek NE, Andresson AM. Metabolism of phthalates in humans. Mol Nutr Food Res 2007;51:899–911.
8 Latini G, De Felice C, Presta G, et al. In utero exposure to di-(2-ethylhexyl)phthalate and duration of human pregnancy. Environ Health Perspect 2003;111:1783–5.
9 Main KM, Mortensen G, Klaeves MM, et al. Human breast milk contamination with phthalates and alterations of endogenous reproductive hormones in infants three months of age. Environ Health Perspect 2006;114:270–6.
10 Suzuki Y, Niwa M, Yoshinaga J, et al. Exposure assessment of phthalate esters in Japanese pregnant women by using urinary metabolite analysis. Environ Health Prev Med 2009;14:180–7.
11 Fowler PA, Bellingham M, Sinclair KD, et al. Impact of endocrine-disrupting compounds (EDCs) on female reproductive health. Mol Cell Endocrinol 2012;355:231–9.
12 Calafat AM, Koch HM, Swan SH, et al. Misuse of blood serum to assess exposure to bisphenol A and phthalates. Breast Cancer Res 2013;15:403–4.
13 Calafat AM, Slakman AR, Silva MJ, et al. Automated solid phase extraction and quantitative analysis of human milk for 13 phthalate metabolites. J Chromatogr B Technol Biomed Life Sci 2004;805:49–56.
14 Koch HM, Gonzalez-Reche LM, Angerer J. On-line clean-up by multidimensional liquid chromatography-electrospray ionization tandem mass spectrometry for high throughput quantification of primary and secondary phthalate metabolites in human urine. J Chromatogr B Analyt Technol Biomed Life Sci 2003;784:169–82.
15 Jimenez-Diaz I, Zafran-Gomez A, Ballesteros O, et al. Determination of bisphenol A and its chlorinated derivatives in placental tissue samples by liquid chromatography-tandem mass spectrometry. J Chromatogr B Technol Biomed Life Sci 2010;878:3363–9.
16 Vela-Soria F, Jimenez-Diaz I, Rodriguez-Gomez R, et al. A multiclass method for endocrine disrupting chemical residue analysis in human placental tissue samples by UHPLC–MS/MS. Anal Methods 2011;3:2073–81.
17 Savransky V, Nanayakkara A, Vivero A, et al. Chronic intermittent hypoxia predisposes to liver injury. Hepatology 2005;41:1007–13.
18 Enke U, Schleussnera E, Pälmkeb C, et al. Misuse of blood serum to assess exposure to bisphenol A and phthalates. Breast Cancer Res 2013;15:403–4.
19 Erke U, Schlesserna E, Paemkeb C, et al. Phthalate exposure in pregnant women and newborns—the urinary metabolite excretion pattern differs distinctly. Int J Hyg Environ Health 2013;216:735–42.
20 Frederiksen H, Kuij-Hanninen T, Main KM, et al. A longitudinal study of urinary phthalate excretion in 58 full-term and 67 preterm infants from birth through 14 months. Environ Health Perspect 2014;122:998–1005.
21 Lin S, Ku HY, Su PH, et al. Phthalate exposure in pregnant women and their children in central Taiwan. Chromosphere 2011;8:947–55.
22 Ye X, Fierik FH, Angerer J, et al. Levels of metabolites of organophosphate pesticides, phthalates, and bisphenol A in pooled urine samples from pregnant women participating in the Norwegian Mother and Child Cohort Study (MoBa). Int J Hyg Environ Health 2009;212:481–91.
23 Koch HM, Bolt HM, Angerer J. Di-(2-ethylhexyl) phthalate (DEHP) metabolites in human urine and serum after a single oral dose of deuterium-labelled DEHP. Arch Toxicol 2004;78:123–30.
24 Koch HM, Bolt HM, Preuss R, et al. New metabolites of di(2-ethylhexyl) phthalate (DEHP) in human urine and serum after single oral doses of deuterium-labelled DEHP. Arch Toxicol 2005;79:367–76.
25 Ligi I, Boubred F, Grandetllum J, et al. The neonatal kidney: implications for drug metabolism and elimination. Curr Drug Metab 2013;14:174–7.
26 Ong KK, Ahmed ML, Emmett PM, et al. Association between postnatal catch-up growth and obesity in childhood: prospective cohort study. BMJ 2000;320:967–71.
26. Kwack SJ, Han EY, Park JS, et al. Comparison of the short term toxicity of phthalate diesters and monoesters in Sprague-Dawley male rats. *Toxicol Res* 2010;26:75–82.
27. Xu Y, Agrawal S, Cook TJ, et al. Di-(2-ethylhexyl)-phthalate affects lipid profiling in fetal rat brain upon maternal exposure. *Arch Toxicol* 2007;81:57–62.
28. Frederich RC, Hamann A, Anderson S, et al. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. *Nat Med* 1995;1:1311–14.
29. Boeke CE, Mantzoros CS, Hughes MD, et al. Differential associations of leptin with adiposity across early childhood. *Obesity* 2013;21:1430–7.
30. Mantzoros CS, Rifas-Shiman SL, Williams CJ, et al. Cord blood leptin and adiponectin as predictors of adiposity in children at 3 years of age: a prospective cohort study. *Pediatrics* 2009;123:682–9.
31. Kaar JL, Brinton JT, Crome T, et al. Leptin levels at birth and infant growth: the EPOCH study. *J Dev Orig Health Dis* 2014;5:214–18.
32. Strauss JF, Gafvels M, King BF. Placental hormones. In: Degroot LJ, ed. *Endocrinology*. Philadelphia, PA: WB Saunders, 1995:2171–206.
33. García RV, Andrade MA, Rios M, et al. Serum leptin levels in normal children: relationship to age, gender, body mass index, pituitary–gonadal hormones and pubertal stage. *J Clin Endocrinol Metab* 1997;82:2840–55.
34. Tome MA, Lage M, Camina JP, et al. Sex-based differences in serum leptin concentrations from umbilical cord blood at delivery. *European J Endocrinol* 1997;137:655–8.
35. Kennedy A, Gettys TW, Watson P, et al. The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. *J Clin Endocrinol Metab* 1997;82:1293–300.
36. Vandentorren S, Zeman F, Morin L, et al. Bisphenol-A and phthalates contamination of urine samples by catheters in the Elfe pilot study: implications for large-scale biomonitoring studies. *Environ Res* 2011;111:761–4.
37. Kim JH, Park HY, Bae S, et al. Diethylhexyl phthalates is associated with insulin resistance via oxidative stress in the elderly: a panel study. *PLoS ONE* 2013;8:e71392.
38. Hoppin JA, Brock JW, Davis BJ, et al. Reproducibility of urinary phthalate metabolites in first morning urine samples. *Environ Health Perspect* 2002;110:515–18.
39. de Cock M, van de Bor M. Obesogenic effects of endocrine disruptors, what do we know from animal and human studies? *Environ Int* 2014;70:15–24.
40. Grun F, Blumberg B. Endocrine disrupters as obesogens. *Mol Cell Endocrinol* 2009;304:19–29.